Vertos Medical Closes $15.5 Million Series D Financing

ALISO VIEJO, Calif.--(Business Wire)--
Medical device company Vertos Medical, Inc., developer of the mild procedure for
lumbar spinal stenosis (LSS), today announced it has completed a $15.5 million
Series D financing. New investor, ONSET Ventures, led the round with additional
participation from existing Vertos investors CHL Medical Partners, Foundation
Medical Partners, Aweida Venture Partners and DFJ Mercury. The funding will be
used to continue U.S. commercialization of the company`s mild technology, the
least invasive surgical procedure for treating LSS, with no implants left
behind.*

"Vertos` mild procedure represents a breakthrough treatment option for a huge
and underserved market of LSS sufferers: those who are no longer responding to
medical management, but who are not yet candidates for traditional invasive
surgeries," said ONSET Ventures Partner and new Vertos board member, John Ryan.
"Behind this procedure are proprietary technology and a top notch management
team with a strategic approach for driving market adoption. We believe this
combination uniquely positions Vertos for significant growth and will provide a
healthy return on our investment."

Approximately 900,000 Americans are in some form of treatment for LSS every
year.1 Many address their LSS symptoms with pain medications or steroid
injections, but these treatments tend to wear off or lose effectiveness over
time. Furthermore, these patients may not be appropriate candidates for
traditional invasive back surgery. mild offers an alternative image-guided
procedure, performed through a portal that is smaller than the diameter of a
pencil.

"This sizeable financing is an important milestone for Vertos and demonstrates
recognition of the market potential of our mild procedure," said James M.
Corbett, president and chief executive officer of Vertos. "We are grateful to
have the backing of high-caliber venture partners, including ONSET Ventures, as
we endeavor to bring the mild solution to physicians and patients across the
country."

About mild

mild is the first minimally invasive surgical treatment to provide immediate and
lasting relief for patients by addressing a primary cause of LSS. Using
proprietary mild devices, the physician removes the bone or tissue that is
causing pressure on the lower spinal canal nerves. Based on initial clinical
use, mild patients experience an average 75 percent reduction in pain and
greater than 70 percent increase in mobility.2 Treating LSS earlier and least
invasively, which mild allows for, reduces overall health care costs.

About Vertos Medical Inc.

Vertos Medical was founded in 2005 to develop a minimally invasive method for
lumbar spine decompression to treat patients with lumbar spinal stenosis (LSS),
a degenerative, age-related narrowing of the lower spinal canal. Its first
proprietary platform technology, called mild (Minimally Invasive Lumbar
Decompression), is the least invasive surgical procedure for treating LSS, with
no implants left behind.
* For more information, visit www.vertosmed.com.

* Vertos mild is FDA cleared for treating central canal stenosis of the lumbar
spine.

1 Derived from the longitudinal CMS database

2 Data on file at Vertos Medical, Inc.

For Vertos Medical
Laura Nobles, 310-795-0497
laura@noblescommunications.com

Copyright Business Wire 2009